TOI

The Oncology Institute, Inc. [TOI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TOI Stock Summary

Top 10 Correlated ETFs

TOI


Top 10 Correlated Stocks

TOI


In the News

10:35 29 Mar 2024 TOI

Down -23.64% in 4 Weeks, Here's Why The Oncology Institute (TOI) Looks Ripe for a Turnaround

The Oncology Institute (TOI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

08:00 29 Mar 2024 TOI

The Oncology Institute Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call

CERRITOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2023 financial results after the market close on Wednesday, March 27, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

10:11 29 Mar 2024 TOI

Penny Stocks To Buy Now? 4 To Watch Before 2024

As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.

03:25 29 Mar 2024 TOI

The Oncology Institute, Inc. (TOI) Q3 2023 Earnings Call Transcript

The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Jack Slevin - Jefferies Operator Good afternoon, and welcome to The Oncology Institute Third Quarter 2023 earnings conference call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.

08:03 29 Mar 2024 TOI

The Oncology Institute Announces Third Quarter 2023 Earnings Release Date and Conference Call

CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2023 financial results after the market close on Wednesday, November 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

04:05 29 Mar 2024 TOI

The Oncology Institute Executive Leaders to Present at the 2023 Association for Value-Based Cancer Care (AVBCC) Summit

CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yale Podnos, and other senior clinical leaders, will be participating in the Association for Value-Based Cancer Care (AVBCC) Summit.

10:18 29 Mar 2024 TOI

The Oncology Institute, Inc. (TOI) Q2 2023 Earnings Call Transcript

The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Taji Phillips - Jefferies Operator Good afternoon ladies and gentlemen and welcome to The Oncology Institute's Second Quarter 2023 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.

08:00 29 Mar 2024 TOI

The Oncology Institute Announces Second Quarter 2023 Earnings Release Date and Conference Call

CERRITOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2023 financial results after the market close on Tuesday, August 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

09:19 29 Mar 2024 TOI

3 Penny Stocks That Have Game-Changing Technologies

The NASDAQ index led the market out of technical bear market territory. And if the rally is going to have legs, investors will know they have artificial intelligence ( AI ) to thank for it.

08:00 29 Mar 2024 TOI

The Oncology Institute Announces First Quarter 2023 Earnings Release Date and Conference Call

CERRITOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2023 financial results after the market close on Wednesday, May 10, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

TOI Financial details

Company Rating
Neutral
Market Cap
101.04M
Income
-73.82M
Revenue
309.88M
Book val./share
0.98
Cash/share
1.19
Dividend
-
Dividend %
-
Employees
750
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-2
Forward P/E
-8.13
PEG
-0.04
P/S
0.48
P/B
2.06
P/C
1.3
P/FCF
-2.84
Quick Ratio
4.21
Current Ratio
4.71
Debt / Equity
1.63
LT Debt / Equity
1.55
-
-
EPS (TTM)
-0.99
EPS next Y
-0.19
EPS next Q
1.57
EPS this Y
-112.88%
EPS next Y
-80.81%
EPS next 5Y
-80.81%
EPS last 5Y
-31.84%
Revenue last 5Y
17.41%
Revenue Q/Q
2.26%
EPS Q/Q
4.35%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
19.67%
Inst Trans
1.04%
ROA
-34%
ROE
-78%
ROC
-0.32%
Gross Margin
20%
Oper. Margin
-19%
Profit Margin
-24%
Payout
-
Shs Outstand
73.75M
Shs Float
30.85M
-
-
-
-
Target Price
8
52W Range
0.33-2.655
52W High
-
52W Low
-
RSI
46
Rel Volume
1.97
Avg Volume
135.62K
Volume
266.97K
Perf Week
9.57%
Perf Month
-13.69%
Perf Quarter
8.04%
Perf Half Y
1.64%
-
-
-
-
Beta
0.722
-
-
Volatility
0.18%, 0.16%
Prev Close
-16.03%
Price
1.545
Change
-10.17%

TOI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.942.412.913.073.13
Net income per share
0.14-0.06-0.22-0.160.02
Operating cash flow per share
0.20.060.01-0.49-0.77
Free cash flow per share
0.170.04-0.01-0.54-0.83
Cash per share
00.040.091.730.92
Book value per share
00.660.441.571.55
Tangible book value per share
00.1-0.090.91.03
Share holders equity per share
00.660.441.571.55
Interest debt per share
000.190.011.39
Market cap
278.88M625.13M696.02M645.75M133M
Enterprise value
0622.68M701.95M531.63M227.17M
P/E ratio
70.64-155.45-48.6-59.180.27
Price to sales ratio
2.464.023.713.180.53
POCF ratio
49.43172.911.37K-19.76-2.15
PFCF ratio
56.39259.31-1.01K-18.07-1.98
P/B Ratio
014.8124.776.21.07
PTB ratio
014.8124.776.21.07
EV to sales
04.013.742.620.9
Enterprise value over EBITDA
02.03K-62.18-12.82-3.39
EV to operating cash flow
0172.241.38K-16.27-3.68
EV to free cash flow
0258.3-1.02K-14.88-3.38
Earnings yield
0.01-0.01-0.02-0.020.01
Free cash flow yield
0.0200-0.06-0.51
Debt to equity
000.4200.87
Debt to assets
000.1800.41
Net debt to EBITDA
0-7.97-0.532.75-1.4
Current ratio
01.61.045.174.37
Interest coverage
3.01K-780.67-23.62-143.31-17.64
Income quality
1.43-0.9-0.042.99-37.27
Dividend Yield
0.030000
Payout ratio
2.080000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00.610.510.220.16
Capex to operating cash flow
-0.12-0.33-2.350.090.09
Capex to revenue
-0.01-0.01-0.01-0.02-0.02
Capex to depreciation
-0.63-0.41-0.38-0.91-1.25
Stock based compensation to revenue
0000.120.11
Graham number
00.961.482.420.85
ROIC
0-0.1-0.2-0.41-0.24
Return on tangible assets
0-0.17-0.45-0.070.01
Graham Net
0-0.03-0.260.52-0.38
Working capital
08.21M1.11M124.26M100.65M
Tangible asset value
06.14M-5.64M59.29M83.31M
Net current asset value
04.49M-7.87M54.78M-8.56M
Invested capital
000.4200.87
Average receivables
0016M19.25M30.88M
Average payables
0010.76M14.1M12.47M
Average inventory
004.12M5.4M7.85M
Days sales outstanding
034.6133.5938.258.58
Days payables outstanding
025.8530.6335.0217.07
Days of inventory on hand
011.3110.5514.4916.87
Receivables turnover
010.5510.879.566.23
Payables turnover
014.1211.9110.4221.38
Inventory turnover
032.2634.625.1921.64
ROE
0-0.1-0.51-0.10.01
Capex per share
-0.02-0.02-0.02-0.05-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.820.831.041.11.12
Net income per share
-0.03-0.11-0.41-0.23-0.24
Operating cash flow per share
-0.26-0.16-0.21-0.12-0.11
Free cash flow per share
-0.27-0.19-0.24-0.13-0.13
Cash per share
1.140.860.750.541.19
Book value per share
1.611.461.341.160.98
Tangible book value per share
0.980.971.040.80.63
Share holders equity per share
1.611.461.341.160.98
Interest debt per share
1.351.291.531.641.63
Market cap
368.46M141.23M49.79M40.02M102.86M
Enterprise value
413.1M235.4M144.58M127.46M192.67M
P/E ratio
-34.45-3.72-0.41-0.59-1.48
Price to sales ratio
5.671.980.650.51.25
POCF ratio
-18.06-10.09-3.22-4.62-12.38
PFCF ratio
-17.07-8.83-2.88-4.17-11.13
P/B Ratio
2.881.130.510.471.43
PTB ratio
2.881.130.510.471.43
EV to sales
6.363.31.91.592.35
Enterprise value over EBITDA
-21.74-17.74-10.8-9.86-16.86
EV to operating cash flow
-20.25-16.82-9.36-14.72-23.19
EV to free cash flow
-19.13-14.72-8.36-13.28-20.85
Earnings yield
-0.01-0.07-0.6-0.42-0.17
Free cash flow yield
-0.06-0.11-0.35-0.24-0.09
Debt to equity
0.830.871.121.371.63
Debt to assets
0.370.410.470.510.54
Net debt to EBITDA
-2.35-7.1-7.08-6.76-7.86
Current ratio
4.374.373.953.114.71
Interest coverage
-13.42-6.18-6.04-5.59-5.17
Income quality
7.631.470.520.510.48
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.180.160.090.120.12
Capex to operating cash flow
0.060.140.120.110.11
Capex to revenue
-0.02-0.03-0.02-0.01-0.01
Capex to depreciation
-1.05-1.67-1.45-0.71-0.55
Stock based compensation to revenue
0.10.080.070.050.06
Graham number
1.11.913.512.472.28
ROIC
-0.08-0.06-0.07-0.06-0.06
Return on tangible assets
-0.01-0.04-0.14-0.08-0.09
Graham Net
-0.42-0.35-0.56-0.89-0.22
Working capital
110.78M100.65M88.88M70.57M120.29M
Tangible asset value
78.25M83.31M76.63M58.15M46.06M
Net current asset value
-12.24M-8.56M-17.27M-41.17M6.18M
Invested capital
0.830.871.121.371.63
Average receivables
32.37M37.95M43.45M46.64M47.9M
Average payables
12.53M10.26M10.66M12.53M13.23M
Average inventory
9.3M9.64M9.76M11.21M12.17M
Days sales outstanding
4951.0654.7952.6153.65
Days payables outstanding
19.3215.1217.3118.1418.17
Days of inventory on hand
17.3514.9414.8616.8216.59
Receivables turnover
1.841.761.641.711.68
Payables turnover
4.665.955.24.964.95
Inventory turnover
5.196.026.065.355.43
ROE
-0.02-0.08-0.3-0.2-0.24
Capex per share
-0.01-0.02-0.03-0.01-0.01

TOI Frequently Asked Questions

What is The Oncology Institute, Inc. stock symbol ?

The Oncology Institute, Inc. is a US stock , located in Cerritos of Ca and trading under the symbol TOI

Is The Oncology Institute, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $8. The lowest prediction is $6 and the highest is $10

What is TOI stock prediction ?

What is The Oncology Institute, Inc. stock quote today ?

The Oncology Institute, Inc. stock price is $1.545 today.

Is The Oncology Institute, Inc. stock public?

Yes, The Oncology Institute, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap